Fairman Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Fairman Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.08K	Hold	11	–	–	﹤0.01%	281
2025 Q4	$1.87K	Buy	+11	New	+$1.69K	﹤0.01%	290

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fairman Group's JAZZ Position: Q1 2026 in Review

Fairman Group held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2026 at 11 shares worth $2.08K. The position accounts for ﹤0.01% of the portfolio, ranked #281.

Fairman Group first reported a position in JAZZ in Q4 2025 and has held it in 2 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Fairman Group held 11 shares of Jazz Pharmaceuticals worth $2.08K as of Q1 2026.
Fairman Group left its Jazz Pharmaceuticals share count unchanged in Q1 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Fairman Group's portfolio in Q1 2026, its #281 holding.
Fairman Group first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Fairman Group's 13F filing for Q1 2026, filed 23 Apr 2026.